Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at :

NCT ID NCT05239910
Title Study to Evaluate the Efficacy and Safety of Tenalisib, Given With CHOP Therapy for Front Line Treatment in Patients With PTCL
Recruitment Withdrawn
Gender both
Phase Phase II
Variant Requirements No
Sponsors Rhizen Pharmaceuticals SA
Age Groups: adult | senior
Covered Countries USA

No variant requirements are available.